FLGT - Fulgent Genetics beats top-line and bottom-line estimates; reaffirms FY25 outlook
2025-05-02 07:02:20 ET
More on Fulgent Genetics
- Fulgent Genetics: Undervalued, CFO Buying, And Promising Drug Candidates Make It A Buy
- Fulgent Genetics, Inc. (FLGT) Q4 2024 Earnings Conference Call Transcript
- Fulgent Genetics Q1 2025 Earnings Preview
- Seeking Alpha’s Quant Rating on Fulgent Genetics
- Historical earnings data for Fulgent Genetics